Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 Years' experience

Vox Sanguinis

Volumn 92, Issue 4, 2007, Pages 319-326

  Politis, C ^a   Kavallierou, L ^a   Hantziara, S ^a   Katsea, P ^a   Triantaphylou, V ^a   Richardson, C ^a   Tsoutsos, D ^a   Anagnostopoulos, N ^a   Gorgolidis, G ^a   Ziroyannis, P ^a  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

Clinical use; Fresh frozen plasma; Methylene blue; Pathogen inactivation

Indexed keywords

BLOOD CLOTTING FACTOR; FRESH FROZEN PLASMA; METHYLENE BLUE;

ARTICLE; BIOSAFETY; BLOOD BANK; BLOOD TRANSFUSION; INFECTION PREVENTION; LEUKAPHERESIS; PLASMA TRANSFUSION; PRIORITY JOURNAL; RISK REDUCTION; SEROCONVERSION;

ANTI-INFECTIVE AGENTS; BLOOD COAGULATION FACTORS; BLOOD TRANSFUSION; CYTOKINES; FILTRATION; GREECE; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; METHYLENE BLUE; PLASMA; PLASMA EXCHANGE; QUALITY CONTROL; SAFETY;

EID: 34247331490     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2007.00898.x     Document Type: Article

References (40)

1. Council of Europe: Pathogen Inactivation of Labile Blood Products, Recommendation R (2003) 11. Strasbourg, Council of Europe Publishing, 2003
2. Commission Directive 2002/ /EC: Setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC. Official Journal of the European Union 2003 L33: 30 40
3. Morgenthaler JJ: Effect of ethanol on viruses. Curr Stud Hematol Blood Transfus 1989 56: 109 121
4. Kempj C, Jentsch P, Poirier B, Barre-Sinoussi F, Morgenthaler JJ, Morell A, Germann D: Virus inactivation during production of intravenous immunoglobulin. Transfusion 1991 31: 423 427
5. Klein HG, Dodd RY, Dzik WH, Luban NL, Ness PM, Pisciotto P, Schiff PD, Snyder EL: Current status of solvent/detergent-treated frozen plasma. Transfusion 1998 38: 102 107
6. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW: Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood 1992 79: 826 831
7. Williamson LM, Cardigan R, Prowse CV: Methylene blue treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003 43: 1322 1329
8. Lambrecht B, Mohr H, Knuver-Hopf J, Schmitt H: Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light. Vox Sang 1991 60: 207 213
9. Mohr H, Lambrecht B, Selz A: Photodynamic virus inactivation of blood components. Immunol Invest 1995 24: 73 85
10. Horowitz B: Pathogen inactivated transfusion plasma: existing and emerging methods. Vox Sang 2002 83: 429 436
11. Chapman J: Virus inactivation of plasma by methylene blue photoinactivation: approaches and toxicology. Transfus Today 1994 20: 2 4
12. Mohr H, Pohl U: Virus inactivation of plasma by methylene blue/light exposure: clinical experiences. Transfus Today 1994 21: 2 3
13. Mohr H, Lambrecht B, Knüver-Hopf J: Virus inactivated single donor fresh plasma preparation. Infusionsther Transfusionsmed 1992 19: 79 83
14. Achour A: Phenothiazines and prion diseases: a potential mechanism of action towards oxidative stress. Int J Antimicrob Agents 2002 20: 305 306
15. Zeiler T, Riess H, Wittmann G, Hintz G, Zimmermann R, Muller C, Heuft HG, Huhn D: The effect of methylene blue phototreatment on plasma proteins and in vitro coagulation capability of single-donor fresh-frozen plasma. Transfusion 1994 34: 685 689
16. Mohr H, Knüver-Hopf J, Lambrecht B, Scheidecker H, Schmitt H: No evidence for neoantigens in human plasma after photochemical virus inactivation. Ann Hematol 1992 65: 1 5
17. Verpoort T, Chollet S, Lebrun F, Goudaliez F, Mohr H, Walker WH: Elimination of methylene blue from photodynamically treated virus inactivated fresh-frozen plasma: the Blueflex filter. Transfus Clin Biol 2001 8: 103s
18. Garwood M, Cardigan RA, Drummond O, Hornsey VS, Turner CP, Young D, Williamson LA, Prowse CV: The effect of methylene blue photoinactivation and methylene blue removal on the quality of fresh-frozen plasma. Transfusion 2003 43: 1238 1247
19. Simonsen AC, Sorensen H: Clinical tolerance of methylene blue virus-inactivated plasma. Vox Sang 1999 77: 210 217
20. Mohr H, Knüver-Hopf J, Gravemann U, Redecker-Klein A, Müller TH: West Nile virus in plasma is highly sensitive to methylene blue-light treatment. Transfusion 2004 44: 886 890
21. Busch MP, Kleinman SH, Nemo GJ: Current and emerging infectious risks of blood transfusions. JAMA 2003 289: 959 962
22. Allain JP, Thomas I, Sauleda S: Nucleic acid testing for emerging viral infections. Transfus Med 2002 12: 275 283
23. Politis C, Kavallierou L, Vagena D, Richardson C, Triantaphyllou V: The contribution of nucleid acid testing (NAT) in blood transfusion safety. Detection of four NAT HBV-DNA positive, HBsAg negative in single blood donations. Abstract P-105 ISBT Cape Town, September 2006
24. Politis C, Richardson C, Damaskos P: Coordinating Haemovigilance Centre (SKAE): Summary Report: 10 Years of Haemovigilance 1995-2005. Athens, Greece, Hellenic Centre of Diseases Control and Prevention (KEELPNO), 2005
25. Hornsey VS, Drummond O, Young D, Docherty A, Prowse CV: A potentially improved approach to methylene blue virus inactivation of plasma: the Maco Pharma Maco-Tronic system. Transfus Med 2001 11: 31 36
26. Guidelines for the Blood Transfusion Services in the United Kingdom, 7th edn. London, The Stationery Office, 2005
27. Council of Europe: Guide for the Preparation, Use and Quality Assurance of Blood and Blood Components, 8th and 11th edn. Strasbourg, Council of Europe Publishing, 2002 and 2004
28. Commission Directive 2005/ /EC: Implementing Directive 2002/98/EC of the European Parliament and of the Council as regards traceability requirements and notification of serious adverse reactions and events. Official Journal of the European Union 2005 L256: 32 37
29. Geiger TL, Perrotta PL, Davenport R, Baril L, Synder EL: Removal of anaphylatoxins C3a and C5a and chemokines interleukin 8 and RANTES by polyester white cell-reduction and plasma filters. Transfusion 1997 37: 1156 1162
30. Willis JI, Lown JA, Simpson MC, Erber WN: White cells in fresh-frozen plasma: evaluation of a new white cell-reduction filter. Transfusion 1998 38: 645 649
31. Rock GA, Shumak KH, Buskard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med 1991 325: 393 397
32. Rock GA, Shumak KH, Sutton DM, Buskard NA, Nair RC: Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Br J Haematol 1996 94: 383 386
33. Yarranton H, Lawrie AS, Purdy G, Mackie IJ, Machin SJ: Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 2004 14: 39 44
34. Council of Europe: The Collection, Testing and Use of Blood and Blood Products in Europe in 2002. Report prepared by Van der Poel CL, Janssen MP. Strasbourg, Council of Europe, 2004
35. Wagner SJ: Virus inactivation in blood components by photoactive phenothiazine dyes. Transfus Med Rev 2002 16: 61 66
36. SHOT Steering Group: Serious Hazards of Transfusion Annual Report, 2000-2001. The Serious Hazards of Transfusion Steering Group, 2002
37. Suontaka AM, Blomback M, Chapman J: Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light. Transfusion 2003 43: 568 575
38. Hornsey VS, Krailadsiri P, MacDonald S, Seghatchian G, Williamson LM, Prowse CV: Coagulation factor content of cryoprecipitate prepared from methylene blue plus light versus virus-inactivated plasma. Br J Haematol 2000 109: 665 670
39. Ramila E, Muniz-Diaz E, Matinez C, Montero A, Pastoret C, Madoz P: Use of methylene blue virus-inactivated plasma in the treatment of thrombotic thrombocytopenic purpura (TTP). Transfus Clin Biol 2001 8: 10s 11s
40. Atance R, Pereira A, Ramirez B: Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion 2001 41: 1548 1552